- PR Newswire•6 days agoIpsen Announces Data Presentation for Dysport® (abobotulinumtoxinA) at American Academy of Cerebral Palsy and Developmental Medicine
ADR: IPSEY), today announced that an additional data analysis regarding the safety and efficacy of repeated treatment sessions of Dysport® (abobotulinumtoxinA) in children (aged 2 and older) with lower limb spasticity will be presented at the annual meeting of the American Academy of Cerebral Palsy and Developmental Medicine (AACPDM) being held in Hollywood, Florida, September 20 – 24, 2016. The data will be shared in an oral presentation of the results of an open label extension of a multicenter, prospective, double-blind, randomized, placebo-controlled study assessing Dysport® in pediatric patients 2 to 17 years of age with lower limb spasticity because of cerebral palsy causing dynamic equinus foot deformity. "We are pleased to present this data at this year's AACPDM meeting, following the FDA's recent approval of Dysport® for the treatment of lower limb spasticity in pediatric patients aged two and older," said Cynthia Schwalm, EVP, North America Commercial Operations, Ipsen.
- PR Newswire•12 days agoIpsen Biopharmaceuticals, Inc. Announces Eight Presentations for Dysport® (abobotulinumtoxinA) at the Annual Meeting of the American Association of Neuromuscular & Electrodiagnostic Medicine
BASKING RIDGE, N.J., Sept. 15, 2016 /PRNewswire/ -- Ipsen Biopharmaceuticals, Inc., a subsidiary of Ipsen SA (Euronext: IPN; ADR: IPSEY) (Ipsen), today announced that eight posters regarding the use of ...
Ipsen S.A. (IPN.PA)
Paris - Paris Delayed Price. Currency in EUR
|Bid||53.26 x 46200|
|Ask||53.99 x 2000|
|Day's Range||60.39 - 61.13|
|52wk Range||45.31 - 63.05|
|1y Target Est||N/A|
|P/E Ratio (ttm)||21.55|
|Avg Vol (3m)||76,579|
|Dividend & Yield||N/A (N/A)|